HemaSphere (Aug 2023)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA

  • Adriano Venditti,
  • Alfonso Piciocchi,
  • Luca Maurillo,
  • Maria Ilaria Del Principe,
  • Raffaele Palmieri,
  • Stefano Soddu,
  • Federico Moretti,
  • Prassede Salutari,
  • Maurizio Martelli,
  • Maria Paola Martelli,
  • Mario Luppi,
  • Alessandro Pulsoni,
  • Francesco Zaja,
  • Roberto Cairoli,
  • Fabrizio Pane,
  • Sergio Siragusa,
  • Renato Bassan,
  • Michela Rondoni,
  • Milena Mirabile,
  • Antonino Mulè,
  • Germana Beltrami,
  • Patrizia Zappasodi,
  • Laura Cudillo,
  • Andrea Mengarelli,
  • Antonio Curti,
  • Felicetto Ferrara,
  • Giovanni Rossi,
  • Ernesta Audisio,
  • Giuseppina Spinosa,
  • Alessia Tieghi,
  • Monica Bocchia,
  • Vincenza Martini,
  • Catello Califano,
  • Luigi Rigacci,
  • Agostino Tafuri,
  • Michele Gottardi,
  • Paola Fazi,
  • Marco Vignetti,
  • Francesco Buccisano

DOI
https://doi.org/10.1097/01.HS9.0000968928.84153.89
Journal volume & issue
Vol. 7
p. e8415389

Abstract

Read online

No abstracts available.